Takeda, Cell Genesys Ink $270 Million GVAX Deal For Prostate Cancer
This article was originally published in The Pink Sheet Daily
Executive Summary
Oncology, urology areas are important to the firm because of huge unmet needs, Takeda tells “The Pink Sheet” DAILY.
You may also be interested in...
Cancer Vaccine Makers Capitalize On Provenge Fanfare At ASCO
Heading into this year's American Society of Clinical Oncology meeting, beleaguered cancer immunotherapy developers finally have some cause for optimism about potential partnerships and, battle-hardened, they say they are hearty enough to wait for deals to roll in
Cancer Vaccine Makers Capitalize On Provenge Fanfare At ASCO
Heading into this year's American Society of Clinical Oncology meeting, beleaguered cancer immunotherapy developers finally have some cause for optimism about potential partnerships and, battle-hardened, they say they are hearty enough to wait for deals to roll in
Cancer Immunotherapy Sees Setback With Failure Of Cell Genesys’ GVAX
Cell Genesys will cut 75 percent of its workforce and explore strategic alternatives after halting development of the prostate cancer vaccine.